Hypothesis

A galactose-conjugated navitoclax prodrug that also releases an NRF2 activator (e.g., dimethyl fumarate) within senescent lysosomes will selectively kill senescent cells while sparing platelets, because NRF2 activation lowers the apoptotic threshold in senescent cells but not in platelets, thereby widening the therapeutic window beyond that of Nav-Gal alone.

Rationale

Senescent cells exhibit elevated lysosomal β-galactosidase activity (>10‑fold) and heightened oxidative stress, which constitutively activates the KEAP1‑NRF2 pathway [5]. NRF2 drives expression of antioxidant genes (HO‑1, NQO1) that paradoxically increase reliance on the BCL‑2 family for survival by modulating mitochondrial redox balance [6]. In platelets, NRF2 is basally low and its pharmacological activation does not significantly alter BCL‑XL‑dependent survival [4]. Thus, co‑delivery of an NRF2 activator with a Bcl‑2 inhibitor should synergize only in senescent cells where oxidative stress primes the mitochondrial apoptosis machinery, while platelets remain resistant to the combined insult.

This builds on the observation that Bcl‑2 inhibitors achieve >20‑fold dose reduction when paired with MCL‑1 inhibitors by exploiting heterogeneous BCL‑2/BCL‑XL/MCL‑1 upregulation across senescent subpopulations [1]. Adding NRF2 activation introduces a third axis—redox‑dependent sensitization—that is absent in platelets, addressing the dose‑limiting thrombocytopenia that blocks clinical translation of navitoclax and venetoclax [4].

Experimental Design

1. Prodrug synthesis: Conjugate navitoclax to galactose via a self‑immolative linker and attach dimethyl fumarate (DMF) through a cleavable carbonate that releases both agents upon β‑galactosidase cleavage.
2. In vitro validation: Treat human senescent fibroblasts and endothelial cells (induced by irradiation) and platelet-rich plasma with the dual prodrug, Nav‑Gal alone, and vehicle. Measure (a) lysosomal drug release using a fluorogenic reporter, (b) annexin V/PI apoptosis, (c) SASP cytokine secretion (IL‑8, MMP‑1/3) via ELISA, and (d) platelet activation markers (CD62P, PAC‑1 binding).
3. In vivo efficacy: Administer the dual prodrug or Nav‑Gal to 20‑month‑old C57BL/6 mice twice weekly for 8 weeks. Assess (a) senescent cell burden via p16^Ink4a^‑GFP flow cytometry in aorta, brain, and kidney, (b) neurovascular coupling using whisker‑stimulated laser‑speckle contrast imaging, (c) cognitive performance in the Morris water maze, and (d) hematologic parameters (platelet count, bleeding time).
4. Mechanistic probes: Use Nrf2‑knockout mice and platelets from Nrf2^fl/fl Pf4‑Cre mice to confirm that the senolytic advantage depends on NRF2 presence in target cells but not platelets.

Predicted Outcomes

• The dual prodrug will show ≥2‑fold greater senescent cell apoptosis in vitro compared with Nav‑Gal at equimolar navitoclax concentrations, while platelet apoptosis remains <5 % (vs ~15 % for Nav‑Gal alone).
• In aged mice, dual prodrug treatment will reduce p16^Ink4a^+ cells by ≥40 % in vasculature and brain, improve neurovascular coupling by ≥25 %, and rescue spatial memory deficits, whereas Nav‑Gal alone will produce modest improvements (<15 %) accompanied by a transient platelet drop (>20 % baseline).
• Nrf2 deficiency in target tissues will abolish the enhanced senolytic effect, confirming the mechanistic dependence on NRF2‑mediated redox sensitization.

Potential Pitfalls and Alternatives

If platelet toxicity is not mitigated, the hypothesis would be falsified, suggesting that NRF2 activation does not sufficiently differentially modulate BCL‑XL dependence between senescent cells and platelets. In that case, alternative strategies—such as incorporating a platelet‑specific de‑protecting moiety (e.g., a GP‑IB‑cleavable peptide) or shifting to a PROTAC‑based BCL‑XL degrader with an NRF2‑responsive promoter—could be pursued. Conversely, a successful outcome would provide a translational path to leverage the mechanistic superiority of Bcl‑2 family inhibitors while matching the safety profile that has enabled dasatinib‑quercetin’s progression into human trials.